Brokerage Reports
0 items in cart
Alnylam Pharmaceuticals, Inc. [ALNY]
Reports for Purchase
Showing records 381 - 400 ( 417 total )
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: RODMAN & RENSHAW, CO.
Price: 25.00
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Price: 10.00
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Price: 25.00
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
LIFE SCIENCESThis report contains brief updates on the following: SUPG, DNDN, SPPI, ALNY, ROSG, ZIOP. These companies are covered in more detail in separate Daily Notes and/or Company Reports.
Provider: RODMAN & RENSHAW, CO.
Analyst: BENJAMIN R
Price: 100.00
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
R&R?s Week in Review: Oncology and Stem Cell Sectors
Provider: RODMAN & RENSHAW, CO.
Analyst: BENJAMIN R
Price: 10.00
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: RODMAN & RENSHAW, CO.
Price: 10.00
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
R&R?s Week in Review: Oncology and Stem Cell Sectors.
Provider: RODMAN & RENSHAW, CO.
Analyst: BENJAMIN R
Price: 10.00
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: RODMAN & RENSHAW, CO.
Price: 25.00
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Oversold in reaction to Roche and Novartis moves; short- and long-term buying
Provider: RODMAN & RENSHAW, CO.
Analyst: SIMEONIDIS S
Price: 10.00
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: RODMAN & RENSHAW, CO.
Price: 25.00
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
With focus now 100% on internal pipeline, Reports 3Q10; expecting liver cancer data next week.
Provider: RODMAN & RENSHAW, CO.
Analyst: SIMEONIDIS S
Price: 10.00
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: RODMAN & RENSHAW, CO.
Price: 25.00
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Life Sciences - R&R?s Week in Review: Oncology and Stem Cell Sectors
Provider: RODMAN & RENSHAW, CO.
Analyst: BENJAMIN R
Price: 10.00
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Novartis passes on option to Alnylam license; days of $100M upfront for platform licenses
Provider: RODMAN & RENSHAW, CO.
Analyst: SIMEONIDIS S
Price: 10.00
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: RODMAN & RENSHAW, CO.
Price: 25.00
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
No major updates on 2Q10 call; Novartis decision on $100M adoption license next major milestone
Provider: RODMAN & RENSHAW, CO.
Analyst: SIMEONIDIS S
Price: 10.00
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: RODMAN & RENSHAW, CO.
Price: 10.00
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Price: 10.00